IL-BAI
8.12.2022 19:43:43 CET | Business Wire | Press release
BAI, a nonprofit independent organization that delivers the most actionable insights in financial services, has named ten organizational winners and one honorable mention for the 2022 BAI Global Innovation Awards. Ten individuals were also named BAI Rising Stars. The awards are the industry’s leading program celebrating achievements in innovation, such as pursuing bold solutions for improving customer experience; implementing advanced technologies; and improving the lives of employees, customers, and communities.
Winners were selected by the BAI Innovation Circle, a panel of distinguished judges from around the world who are at the forefront of innovation in the financial services sector. Collectively, the winners represent outstanding contributions by teams and individuals and showcase inspiration from around the world. These global trailblazers have successfully designed and delivered innovations that positively improved customer relationships and served their communities in powerful ways.
“Innovation is a significant driver of the impact that successful financial services companies have on their customers and communities. The industry continues to bring powerful new approaches and solutions to better meet customer needs in new and different ways,” said Debbie Bianucci, president and CEO of BAI and Innovation Circle Judge. “The companies and individuals recognized this year were particularly creative and focused on addressing practical issues that made meaningful improvements for customers and employees.”
The 2022 BAI Global Innovation Award Winners and Honorable Mention are:
Banco Popular (Puerto Rico)
Innovation in Learning & Development
Innovation: Talent Lab & Skills Accelerator
Bank of America (USA)
Innovation in Digital Security
Innovation: Bank of America Security Center
Dreams Technology (United Kingdom)
Innovation in Digital Financial Planning
Innovation: Dreams ESG Innovation
Growsari (Philippines)
Innovation in Digital Commercial Financing
Innovation: GROWSARI.com, Powering the Digital Economy of the Philippines
Money Management International, Inc. (USA)
Innovation in Community Disaster Recovery
Innovation: Project Porchlight by MMI
MVB Bank (USA)
Innovation in Commercial Banking Onboarding Experience
Innovation: Onboarding Fintechs Better, Faster, Stronger…The Victor (ad)Vantage
Payten Teknoloji A.S.-Paratika (Turkey)
Innovation in Payments
Innovation: Paratika Crowdfunding e-Payment Project
Standard Bank (South Africa)
Innovation in Community Sustainability
Innovation: One Farm Share
TIAA (USA)
Innovation in Fraud Prevention
Innovation: TIAA Phone Authentication Risk Management (PARM)
Union Bank of India (India)
Innovation in HR Transformation
Innovation: Union Prerna
BMO (USA)
Innovation in Diversity, Equity & Inclusion (Honorable Mention)
Innovation: True Name
To further recognize innovation in financial services, a new award was established in 2022 to recognize individual leaders. The BAI Rising Star Award honors individuals who are up-and-coming leaders in financial services innovation. Leaders were nominated by their organizations and the recipients of the BAI Rising Star Award were selected based on their impact on and passion for innovation and their ability to drive positive change in their organizations.
The 2022 BAI Rising Star Award Winners are:
Sachin Chandna (United Arab Emirates), SVP, Head of Customer Intelligence & Engagement – Emirates NBD
Geoff Ellis (USA), Senior Director Application Development – Ally Financial
Ashley Fiore (USA), Chief Business Intelligence Officer – KlariVis
Snigdha Kumar (USA), Head of Product Operations – Digit
Larricia Lumpkins (USA), SVP, Senior Strategy Manager – Citizens Financial Group
Niki Neumann (South Africa), Executive, Lead Ecosystem Agriculture – Standard Bank Group
Dr. Chetna Pandey (India), Deputy General Manager – Union Bank of India
Stacy Regnier (USA), SVP, Retail Strategic Programs and Business Transformation – Commerce Bank
Bradwin Roper (South Africa), CEO – FNB Connect
Paul Whelpton (South Africa), Group Analytics Officer and Group Head of Trading – JUMO
For more information about the winners and their innovations, visit https://www.bai.org/globalinnovations/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221208005871/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom